ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Tuesday, October 28, 2025

10:30AM-12:30PM: Abstract Number: LB10

Four-Year Safety and Efficacy of Deucravacitinib in Systemic Lupus Erythematosus: Results From a Phase 2 Program

(LB01–LB18) Late-Breaking Posters

10:30AM-12:30PM: Abstract Number: 2119

Fracture rates in 6475 individuals with osteogenesis imperfecta stratified by age, sex and clinical severity

(2106–2123) Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science Poster II

10:30AM-12:30PM: Abstract Number: 2534

Frequency of Ocular and Gastrointestinal Lesions Is Increased in Japanese Behçet’s Disease Patients with HLA-B61

(2524–2546) Vasculitis – Non-ANCA-Associated & Related Disorders Poster III

10:30AM-12:30PM: Abstract Number: 1813

Frequency of Tissue-Specific Activated CD8+ T Cells is Correlated To Disease Severity in Juvenile Idiopathic Arthritis

(1809–1829) Pediatric Rheumatology – Basic Science Poster

10:30AM-12:30PM: Abstract Number: 2313

From Plaque to Plaque: Bridging Oral and Systemic Inflammation in Psoriasis and PsA

(2305–2337) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster III

10:30AM-12:30PM: Abstract Number: 2096

Gamification and Social Incentivization to Promote Physical Activity in Adults with Knee Osteoarthritis: Results from a Multi-Site Randomized Trial

(2079–2105) Osteoarthritis – Clinical Poster II

10:30AM-12:30PM: Abstract Number: 2322

Gender-related Differences in Peripheral and Axial Spondyloarthritis

(2305–2337) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster III

10:30AM-12:30PM: Abstract Number: 2260

Generative AI model identifies patients with Rheumatoid Arthritis (RA) months prior the diagnosis date: results from a large real-world RA cohort

(2227–2264) Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster III

10:30AM-12:30PM: Abstract Number: 1823

Genome-Wide DNA Methylation Analysis in Familial Mediterranean Fever

(1809–1829) Pediatric Rheumatology – Basic Science Poster

10:30AM-12:30PM: Abstract Number: 1891

Geographic Trends in the Burden of Gout in the United States from 1990 to 2021: A State-Level Analysis of Prevalence, Incidence, and Disability

(1877–1913) Epidemiology & Public Health Poster III

10:30AM-12:30PM: Abstract Number: 2475

GERD Severity, Proton Pump Inhibitor Use, and Longitudinal Forced Vital Capacity in the CONQUER Registry

(2470–2503) Systemic Sclerosis & Related Disorders – Clinical Poster III

10:30AM-12:30PM: Abstract Number: 2153

Giant Coronaries in Children with Kawasaki Disease: A Single Centre Experience

(2124–2158) Pediatric Rheumatology – Clinical Poster III

10:30AM-12:30PM: Abstract Number: 1868

Global Downregulation of Fli1 in Mice Induces Cardiac Dysfunction via Enhanced β-fatty acid Oxidation and Collagen Deposition

(1855–1876) Systemic Sclerosis & Related Disorders – Basic Science Poster II

10:30AM-12:30PM: Abstract Number: 1860

GLUT and FAPα as molecular imaging markers for interstitial lung disease in systemic sclerosis

(1855–1876) Systemic Sclerosis & Related Disorders – Basic Science Poster II

10:30AM-12:30PM: Abstract Number: 1777

Granzyme B as a regulator of interferon alpha production in cutaneous lupus erythematosus

(1770–1779) Cytokines & Cell Trafficking Poster

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].